Showing 7031-7040 of 7495 results for "".
- CMS Assigns Q-code to Fish Skin Technology, Kerecis Reportshttps://practicaldermatology.com/news/20141113-cms_assigns_q-code_to_fish_skin_technology_kerecis_reports/2459065/The new Omega3 tissue-regeneration material from Kerecis Limited—dubbed fish skin—has received a "Q" code from the Centers for Medicare and Medicaid Services (CMS). Kerecis Omega3 Wound, indicated for the management of chronic wounds including diabetic, vascular and other hard-to-heal wounds, has b
- Foamix Receives USPTO Patents for Topical Tetracyclineshttps://practicaldermatology.com/news/20141113-foamix_receives_uspto_patents_for_topical_tetracyclines/2459066/Foamix Pharmaceuticals Ltd., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that the United States Patent and Trademark Office ("USPTO") has recently issued to it two additi
- Skin Cancer Foundation: Dermatologists and Beauty Professionals Team Up to Spot Skin Cancershttps://practicaldermatology.com/news/20141113-skin_cancer_foundation_dermatologists_and_beauty_professionals_team_up_to_spot_skin_cancers/2459069/The Skin Cancer Foundation is encouraging dermatologists and beauty professionals to work together through an education program called Heads Up! The skin cancer awareness program provides beauty professionals, including hair stylists and aestheticians, with tips on what to look for, and how to speak
- Brodalumab Outperforms Ustekinumab in Head-to-Head Trialhttps://practicaldermatology.com/news/20141112-brodalumab_outperforms_ustekinumab_in_head-to-head_trial/2459070/New findings from the Phase III AMAGINE-3 trial suggest that the investigational IL-17 inhibitor brodalumab (Amgen/AstraZeneca) may be superior to ustekinumab in treating patients with moderate to severe psoriasis. In the study, investigators evaluated more than 1,800 patients who were randomized to
- Dr. Mary Lupo Joins Aquavit Pharmaceuticals' Scientific Advisory Boardhttps://practicaldermatology.com/news/20141106-dr_mary_lupo_joins_aquavit_pharmaceuticals_scientific_advisory_board/2459072/Mary Lupo, MD, FAAD has joined the US Scientific Advisory Board of Aquavit Pharmaceuticals. Dr. Lupo is a board-certified dermatologist who is internationally recognized for non-surgical skin rejuvenation. In 1984, she opened
- Women's Rogaine 5% Minoxidil Topical Aerosol Receives FDA Approvalhttps://practicaldermatology.com/news/20141104-womens_rogaine_5_minoxidil_topical_aerosol_receives_fda_approval/2459075/The official launch to market of Women's Rogaine 5% Minoxidil Topical Aerosol, once-daily use treatment for Female Pattern Hair Loss containing 5 percent minoxidil in an elegant foam formula. Minoxidil is the only topical ingredient FDA-approved to help regrow hair. Women's Rogai
- Study Finds that the Use of MelaFind Reduced Benign Biopsies by 61% in Patients at Risk for Melanomahttps://practicaldermatology.com/news/20141024-study_finds_that_the_use_of_melafind_reduced_benign_biopsies_by_61_in_patients_at_risk_for_melanoma/2459079/The study, conducted independently and not sponsored by MELA Sciences, Inc. had an initial cohort of 166 pigmented lesions on 30 patients were identified as suspicious by visual inspection and dermoscopy. 64 of those lesions were identified for biopsy and 102 were selected for continued observati
- Restoration Robotics has Harvested the 10 Millionth Hair with the Artas® Robotic Systemhttps://practicaldermatology.com/news/20141024-restoration_robotics_has_harvested_the_10_millionth_hair_with_the_artas_robotic_system/2459080/Dr. Eduardo López Bran, a member of the International Society of Hair Restoration Society said, "We are excited to have harvested the 10 millionth hair. “It is important that my practice continues to offer the most advanced hair restoration procedures to our patients. The ARTAS Robotic Sys
- FDA Advisory Committee Recommends Approval of Secukinumab for Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/20141020-fda_advisory_committee_recommends_approval_of_secukinumab_for_moderate_to_severe_plaque_psoriasis/2459081/The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the FDA voted 7 to 0 to support the approval of AIN457 (secukinumab), a selective interleukin-17A (IL-17A) inhibitor, for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates
- New Data for Topical Nitric Oxide Nanoparticles: Evidence in Animal Model of EDhttps://practicaldermatology.com/news/20141014-new_data_for_topical_nitrous_oxide_nanoparticles_evidence_in_animal_model_of_ed/2459086/Topically applied nitric oxide-releasing nanoparticles (NO-NPs) induced spontaneous erections and increased basal ICP in an animal model of radical prostatectomy. According to findings published in The Journal o